The Hidden Cardiovascular Risks of Cancer Treatments (BETA- FOR INTERNAL USE ONLY)

Beyond Survival
A Cardiologist’s Perspective with Dr. Hwaida Hannoush

By: Lennard Goetze, Ed.D  |  Daniel Root  |  Regina Bessler, PhD

In an era when medicine is becoming increasingly specialized, few physicians are as committed to bridging disciplines as Dr. Hwaida Hannoush, a cardiologist and functional medicine practitioner whose work reflects the growing need for more personalized, predictive, and preventive care. As the founder of Precimed Clinic, Dr. Hannoush has built her clinical philosophy around one central belief: that precision medicine must be at the heart of modern healthcare.

With a strong focus on women’s heart health, preventive cardiology, and individualized treatment strategies, Dr. Hannoush combines the rigor of traditional cardiovascular medicine with the systems-based insight of functional medicine. Her approach is rooted in uncovering the deeper drivers of disease rather than simply managing symptoms. At Precimed Clinic, that means using advanced diagnostics, nuanced interpretation, and personalized care plans to help patients understand the “why” behind their cardiovascular risk—and, where possible, reverse it.

But in a recent discussion about cancer rehabilitation and survivorship, Dr. Hannoush turned her attention to a topic that remains dangerously under-recognized in mainstream medicine: the cardiovascular consequences of cancer therapy. Her message was clear, urgent, and clinically significant: for many cancer survivors, the battle does not end when the tumor is gone.

The Overlooked Crisis in Cancer Survivorship

Much of the public conversation around cancer treatment centers on remission, recurrence, and tumor response. But according to Dr. Hannoush, there is another threat quietly affecting survivors long after treatment has ended: cardiovascular injury. “I want to highlight,” she said, “that for many cancer survivors, cardiovascular side effects of chemotherapy become a serious — and often unrecognized — long-term threat.” That observation reframes the survivorship conversation in an important way.

While cancer therapies are often life-saving, many of them can place profound stress on the cardiovascular system. These effects may not always be immediately visible, but over time they can contribute to heart failure, arrhythmias, coronary disease, vascular dysfunction, metabolic injury, and long-term decline in physical resilience. Research shows that as cancer treatments become more effective and survival extends, cardiovascular disease increasingly emerges as a dominant competing risk — underscoring why protecting the heart during and after cancer treatment is not optional, but essential.

This is the domain of cardio-oncology, an evolving field focused on protecting heart health before, during, and after cancer treatment. Dr. Hannoush has seen its importance firsthand, particularly through her previous work evaluating heart function in patients undergoing aggressive therapies.

She explained that this is not a fringe concern or a rare side effect. In many cases, cardiovascular complications become the dominant long-term health threat in cancer survivors, particularly when these patients are not proactively monitored.  What sets Dr. Hannoush apart from many cardiologists is that she brings a second, complementary lens to this work: functional medicine. While cardio-oncology guidelines focus on monitoring heart function, managing cardiovascular risk factors, and intervening when damage is detected, functional medicine asks a deeper upstream question — why is this particular patient’s body uniquely vulnerable, and what can be done to strengthen its resilience before and after treatment begins? It is the integration of both frameworks that defines her approach to survivorship care.

 

Why the Heart Is So Vulnerable

One of the strengths of Dr. Hannoush’s perspective is her ability to explain cardiac injury not as a single event, but as a multi-layered biological process.

According to her, chemotherapy and related treatments can harm the cardiovascular system through several overlapping mechanisms. First, some drugs can cause direct injury to the myocardium, the muscular tissue of the heart itself. Others disrupt the mitochondria, the energy-producing structures that are especially abundant in cardiac tissue. “The heart is rich in mitochondria,” she explained, “which is the power source.”

When mitochondrial function is impaired, the heart may continue beating, but it does so with reduced cellular efficiency and diminished reserve.  Research confirms that drugs like doxorubicin cause mitochondrial oxidative stress, impaired energy production, and accelerated cell death in cardiac tissue — and that a patient’s individual mitochondrial biology can influence how vulnerable their heart is to this damage, pointing toward a future of more personalized cardiac risk assessment.

Cancer treatments can also affect the coronary arteries, promoting atherosclerosis and increasing the risk of infarction or heart attack. At the same time, they may alter glucose regulation, insulin sensitivity, lipid metabolism, oxidative stress, and inflammatory burden—all of which increase cardiovascular risk even further.

Dr. Hannoush also emphasized the role of hormonal disruption, especially in therapies that suppress sex hormones. In both women and men, these hormonal shifts can have significant effects on vascular function, metabolism, and heart health. And perhaps most compellingly, she pointed to a mechanism often left out of conventional oncology conversations: the gut-heart axis.

“Gut dysbiosis is a very important side effect of chemotherapy,” she said. Because gut health influences inflammation, immune regulation, neurotransmitter production, and metabolic stability, its disruption can have ripple effects far beyond digestion. Emerging preclinical evidence supports this concern: chemotherapy-induced gut dysbiosis can increase intestinal permeability, allowing bacterial products to enter the bloodstream and drive systemic inflammation that worsens cardiovascular injury — a pathway now being studied as part of the gut-microbiota-heart axis. While direct proof in humans is still developing, the mechanistic evidence is compelling and growing.

One cardiovascular risk that deserves particular mention — especially for readers who have undergone treatment for breast cancer, Hodgkin lymphoma, or lung cancer — is radiation therapy. When radiation involves the chest, it can damage the coronary arteries, heart valves, and the pericardial sac through a process of chronic inflammation and scarring. What makes this especially difficult to detect is that these effects can remain silent for years or even decades after treatment ends. Long-term survivors who received chest radiation as recently as their twenties or thirties may not see cardiovascular consequences until midlife — making awareness and surveillance in this population critically important.

Taken together, these mechanisms reveal a difficult truth: many cancer treatments affect not only the tumor, but the body’s foundational systems of resilience.

The Problem with Waiting Too Long

A major concern for Dr. Hannoush is that conventional monitoring often catches cardiovascular damage too late. Traditionally, clinicians look for a decline in ejection fraction (EF) ― a measure of how much blood the heart pumps out with each beat. But by the time EF drops, injury may already be well underway.

That is why she strongly advocates strain imaging, a more sensitive technique that evaluates subtle deformation in the heart muscle before overt dysfunction appears. “You don’t want to wait till the heart function drops,” she explained. “You want to detect it earlier.”

This technology, commonly referred to as longitudinal strain, has become a valuable tool in cardio-oncology because it can reveal subclinical deterioration in the myocardium before symptoms emerge and before standard imaging appears abnormal.

For Dr. Hannoush, this represents one of the clearest examples of what precision medicine should look like in practice: not reactive care, but early detection, functional monitoring, and intervention before collapse. She also emphasized that such monitoring should not be sporadic or incidental. Oncology patients, she argued, should have structured cardiovascular protocols that include echocardiograms, biomarker tracking, and ongoing surveillance tailored to their treatment exposure.

Cancer Rehab Must Be More Than Physical Therapy

Another central theme in Dr. Hannoush’s discussion was the need to redefine what “rehabilitation” actually means after cancer treatment. From her perspective, true recovery is not limited to mobility or strength training. It must include the broader restoration of the systems that treatment may have disrupted—the heart, skeletal muscle, metabolism, hormones, nutrition, detoxification pathways, and even the microbiome.

She specifically highlighted skeletal muscle as a major but often neglected player in survivorship. “Muscles are very important,” she said, noting that skeletal muscle functions as a kind of metabolic organ. It helps regulate insulin sensitivity, glucose uptake, and systemic energy balance. When cancer treatment contributes to muscle loss or frailty, the patient does not just become weaker—they become metabolically more vulnerable. What is perhaps most striking is that this vulnerability extends directly to the heart itself. Research shows that chemotherapy-induced muscle wasting can involve the myocardium — a phenomenon known as cardiac wasting — which thins the ventricular wall, raises cardiac stress, and can contribute to arrhythmias and heart failure independently of the direct toxic effects of the drugs. Protecting skeletal muscle and protecting the heart, it turns out, are not separate goals.

That is one reason why she sees rehabilitation as something far broader than conventional exercise recovery. It must also include metabolic rebuilding, nutrient replenishment, and resilience restoration.

One Size Does Not Fit All

Perhaps the most defining principle in Dr. Hannoush’s philosophy is her insistence that no two patients should be treated as biologically identical. “One size does not fit all,” she said plainly. That statement applies not only to cancer treatment, but to what comes after it.

This is where Dr. Hannoush’s functional medicine training becomes most distinct. Standard cardio-oncology guidelines — supported by major cardiac societies — focus on monitoring ejection fraction and strain, managing blood pressure and cholesterol, and initiating medications when cardiovascular risk is identified. These are essential and evidence-based. But functional medicine, as practiced by Dr. Hannoush, asks what lies beneath those numbers: What is this patient’s individual metabolic reserve? How are they processing and eliminating the chemical burden of treatment? What nutritional or hormonal imbalances are amplifying their vulnerability? These questions, she believes, are just as important as the clinical measurements and often go unasked.

In her view, survivorship care should be personalized using tools such as:

• Nutrigenomics
• Pharmacogenomics
• Metabolomics
• Advanced nutrient and functional testing
• Individualized detoxification assessment
• Cardiovascular and metabolic monitoring

This is especially important because two patients can receive the same therapy and emerge with dramatically different outcomes depending on their baseline reserves, detoxification capacity, nutrient status, hormonal balance, and metabolic health. “It’s not only about the outside toxins,” she noted. “Chemotherapy is one of the toxins, of course. And you need to know how your body is able to detoxify.”

That perspective — grounded in functional medicine’s core principle of identifying root causes rather than managing symptoms — broadens the survivorship conversation in an important way. Rather than viewing side effects as unavoidable collateral damage, Dr. Hannoush challenges clinicians to ask a more useful question: what can be measured, supported, and personalized before the damage becomes permanent?

An Awareness Gap That Must Be Closed

Dr. Hannoush also noted that the field still carries significant blind spots — and that women are among those most affected by them. Sex and racial differences in how cancer therapies damage the heart remain poorly understood, and most foundational cardio-oncology research has not been designed with these differences in mind. Women who have undergone treatment for breast cancer — many of whom received anthracycline-based chemotherapy, HER-2 inhibitors, aromatase inhibitors, or chest radiation represent a large and growing population of survivors with elevated cardiovascular risk. Yet the evidence base to guide their care remains incomplete. For readers of this publication, that gap is not abstract: it is personal. Advocating for thorough cardiovascular surveillance after cancer treatment is not overcaution: it is self-knowledge

Despite the growing evidence in support of cardio-oncology and personalized survivorship care, Dr. Hannoush believes one of the greatest barriers is still lack of awareness. Many patients are never fully informed about what to watch for after treatment. Some assume that once chemotherapy is complete, the danger has passed. Others may not connect symptoms like fatigue, exercise intolerance, palpitations, weight gain, or metabolic instability to prior treatment exposure.

That silence, she suggests, is part of the problem. For now, she believes the most realistic first step is not perfection—it is education. “Raising awareness will be good as a start,” she said.

That awareness must extend to patients, caregivers, oncologists, cardiologists, and the broader rehab community. Because if survivorship is truly the goal, then medicine must stop measuring success only by tumor shrinkage and begin asking a more complete question:

What did the treatment save—and what did it cost? In that conversation, Dr. Hwaida Hannoush offers a voice that is both scientifically grounded and clinically humane. Her work reminds the medical world that surviving cancer should not mean silently inheriting a second chronic disease. If precision medicine is truly the future, then survivorship care must become just as precise.

_______________________________________________________________________________

ABOUT THE AUTHOR

Dr. Hwaida Hannoush is a board-certified cardiologist recognized for her work in women’s cardiovascular health, metabolic medicine, and healthy aging. She blends evidence-based cardiology with preventive and functional strategies to help patients protect heart health while improving long-term vitality. Her clinical focus explores how inflammation, insulin resistance, hormonal changes, stress, and lifestyle patterns influence cardiovascular risk—particularly in women and adults navigating midlife transitions. Known as both a physician and educator, Dr. Hannoush promotes early detection, personalized care, and multidisciplinary collaboration that integrates nutrition, endocrinology, and wellness principles to support stronger hearts and longer, healthier lives.

References

1. Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M., Bergler-Klein, J., ... & ESC Scientific Document Group. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244
2. Camilli, M., Del Buono, M. G., Sanna, T., & Abbate, A. (2024). Anthracycline cardiotoxicity in adult cancer patients: JACC state-of-the-art review. JACC: CardioOncology, 6(5), 643–660. https://doi.org/10.1016/j.jaccao.2024.07.016
3. Koutsoukis, A., Ntalianis, A., Repasos, E., Kastritis, E., Dimopoulos, M. A., & Paraskevaidis, I. (2018). Cardio-oncology: A focus on cardiotoxicity. European Cardiology Review, 13(1), 64–69. https://doi.org/10.15420/ecr.2018:4:2
4. Dobson, R., Ghosh, A. K., Ky, B., Marwick, T., Stout, M., Harkness, A., & Senior, R. (2021). British Society of Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. JACC: CardioOncology, 3(1), 1–16. https://doi.org/10.1016/j.jaccao.2021.01.011
5. Belger, C., Friedmann Angeli, J. P., & Bruns, D. R. (2024). Doxorubicin-induced cardiotoxicity and risk factors. Biomedicine & Pharmacotherapy, 170, 115980. https://doi.org/10.1016/j.biopha.2023.115980
6. Qiu, Y., Gao, J., Chen, Y., & Wang, J. (2023). Anthracycline-induced cardiotoxicity: Mechanisms, monitoring, and prevention. Frontiers in Cardiovascular Medicine, 10, 1242596. https://doi.org/10.3389/fcvm.2023.1242596
7. Gent, D. G., Dent, S., & Lyon, A. R. (2023). The 2022 European Society of Cardiology cardio-oncology guidelines: Key messages for clinical practice. Cardiac Failure Review, 9, e18. https://doi.org/10.15420/cfr.2023.08
8. Bloom, M. W., Herrmann, J., Ky, B., & Lenihan, D. J. (2025). Cardio-oncology and heart failure: A scientific statement from the Heart Failure Society of America. Journal of Cardiac Failure, 31(2), 145–170.
9. Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 188(1), 21–36. https://doi.org/10.1007/s10549-021-06205-8
10. Mecinaj, A., Gulati, G., Heck, S. L., & Omland, T. (2024). Impact of the ESC cardio-oncology guidelines biomarker criteria in anthracycline-treated breast cancer patients. JACC: CardioOncology, 6(1), 85–97.
11. Mallidi, J., Lenneman, C., & Herrmann, J. (2024). Management of cancer therapy-related cardiac dysfunction in clinical practice. American Journal of Cardiology, 214, 88–99.
12. Witteles, R. M., & Telli, M. L. (2022). ESC cardio-oncology guidelines: A triumph—but are we ready for implementation? JACC: CardioOncology, 4(4), 639–642. https://doi.org/10.1016/j.jaccao.2022.10.002

LYMPH NODE REMOVAL IN BREAST CANCER

A Survival Issue and the Fight to Prevent Lymphedema

By: Lennard M. Goetze, Ed.D and RehabScan.org

---

Introduction

Breast cancer is often perceived as a woman’s disease—but for thousands of men diagnosed each year, that misconception creates dangerous gaps in awareness, education, and survivorship care. One of the most overlooked consequences of treatment—particularly for men—is what happens after lymph node removal.

While lymph node surgery is essential for staging and guiding therapy, it can permanently alter the body’s lymphatic system. The result? A lifelong risk of lymphedema, a condition that is frequently underdiagnosed, undertreated, and misunderstood—especially in male patients.

For both men and women, the conversation must evolve. This is not just about removing cancer. It is about preserving function, preventing complications, and restoring quality of life.

---

Why Lymph Nodes Are Removed in Breast Cancer

Lymph nodes serve as biological checkpoints—filtering fluid, trapping pathogens, and, critically, capturing cancer cells that attempt to spread beyond the primary tumor. In breast cancer, the first destination for migrating cancer cells is often the lymph nodes in the underarm (axillary region). As outlined in the original reference material , surgeons remove these nodes to determine whether cancer has spread and to guide decisions about chemotherapy, radiation, and long-term management.

For men, whose breast tissue is minimal and whose diagnoses are often delayed, lymph node involvement can be more common at the time of detection—making node removal even more likely.

---

The Hidden Aftermath: Lymphedema

When lymph nodes are removed or damaged, the body loses part of its drainage system. Lymph fluid—rich in proteins and immune cells—can accumulate in surrounding tissues, leading to swelling, inflammation, and long-term structural changes. This condition, known as lymphedema, can affect:

• The arm and hand
• The chest wall
• The back or flank

While often associated with women, men are equally at risk—and frequently less prepared. Why? Because male breast cancer patients are rarely given the same level of preoperative education about lymphatic health. Many are unaware of early warning signs until the condition has progressed.

---

Men and Lymphedema: The Awareness Gap

Male breast cancer represents less than 1% of all breast cancer cases, but that rarity comes at a cost:

• Fewer tailored educational resources
• Lower clinical suspicion for complications
• Delayed reporting of symptoms

Men may dismiss early swelling as muscle strain or weight fluctuation. Others may avoid reporting symptoms altogether, due to stigma or lack of awareness. This is a critical failure point in survivorship care. Lymphedema does not discriminate by gender—but education often does.

---

Surgical Approach Matters

Not all lymph node surgeries carry the same level of risk.

• Sentinel Lymph Node Biopsy (SLNB): Removes only a few key nodes. Lower risk.
• Axillary Lymph Node Dissection (ALND): Removes multiple nodes. Higher risk.

Radiation therapy to the lymph node region can further impair lymphatic flow, increasing the likelihood of long-term complications. For male patients—who often present with more advanced disease—ALND is more common, placing them at heightened risk from the outset.

---

Early Detection: The New Standard

The traditional model—waiting for visible swelling—is outdated. Today, the goal is early detection and prevention, using:

• Baseline limb measurements
• Bioimpedance spectroscopy
• Functional imaging (ultrasound, lymphatic mapping)

This aligns with a broader movement in modern medicine: identifying dysfunction before it becomes disease.

---

Prevention Strategies for Men and Women

1. Arm Protection Is Critical: The affected arm becomes more vulnerable to infection and inflammation.

Avoid:

• Blood draws and injections in that arm
• Blood pressure cuffs
• Trauma (cuts, burns, heavy strain)

This applies equally to men—especially those returning to physical labor or fitness routines.

---

2. Movement Is Non-Negotiable

The lymphatic system depends on motion.

Recommended:

• Gentle range-of-motion exercises post-surgery
• Progressive strength training
• Daily activity (walking, light resistance work)

Men, in particular, may attempt to “push through” recovery. The key is progressive—not aggressive—loading.

---

 

3. Compression as a Preventative Tool

Compression garments are not just reactive—they can be preventative. Use during:

• Air travel
• Intense physical activity
• Early signs of swelling

Proper fitting is essential.

---

4. Manual Lymphatic Drainage (MLD)

A specialized therapy that helps reroute lymph fluid.

Benefits:

• Reduces swelling
• Improves circulation
• Maintains tissue integrity

Often underutilized in male patients due to lack of referral.

---

5. Weight and Metabolic Health: Higher body mass is associated with increased lymphedema risk.

A structured approach to:

• Nutrition
• Body composition
• Inflammation control is essential for long-term outcomes.

---

 

The Missing Link: REHABILITATION

This is where the conversation must expand—especially within the mission of the Male Breast Cancer Global Alliance. Surgery is not the finish line. It is the starting point for rehabilitation. A comprehensive rehab model should include:

1. Lymphatic Rehabilitation

• Lymphedema therapy (MLD, compression, drainage techniques)
• 
  Ongoing monitoring of fluid dynamics

2. Musculoskeletal Recovery

• Shoulder mobility restoration
• Postural correction
• Scar tissue management

3. Neurological and Functional Recovery

• Addressing nerve irritation or damage
• Restoring coordination and strength

4. Exercise Oncology Integration

• Supervised strength training
• Cardiovascular conditioning
• Fatigue reduction

5. Psychosocial Support

• Identity restoration (especially critical for men)
• Addressing stigma and isolation
• Rebuilding confidence in physical function

---

 

A New Model: From Treatment to Restoration

The future of cancer care must shift from a singular focus on tumor removal to a broader commitment to whole-body restoration. This includes:

• Active surveillance of lymphatic function
• Integration of rehabilitation as a standard of care
• Cross-disciplinary collaboration (oncology, rehab, imaging, integrative care)

For men, this also means normalizing the conversation—bringing male breast cancer and its complications out of the shadows.

---

Conclusion

Lymph node removal saves lives—but it also changes lives. For both men and women, the risk of lymphedema represents a critical intersection between treatment and survivorship. And for men, the challenge is even greater due to lack of awareness, delayed education, and limited resources. The solution is clear:

• Educate early
• Monitor continuously
• Rehabilitate aggressively—but intelligently

 Breast cancer care must no longer end when the tumor is removed. It must extend into a structured, proactive system of recovery—one that protects the lymphatic system, restores physical function, and honors the full journey of survivorship. Because survival is not enough. The goal is to return every patient—man or woman—to strength, movement, and quality of life.

 

2026 Clinical Review on Cancer Rehab

Beyond Survival: Why Cancer Rehabilitation Must Catch Up to Modern Oncology

By Ben Ho Park, MD, PhD, Breast Oncologist

Cancer care has entered a remarkable era of innovation. Today’s therapies are more targeted, more personalized, and in many cases more effective than ever before. Patients are living longer, surviving more complex disease, and benefiting from breakthroughs that would have been unimaginable a generation ago. But with this progress comes a new and urgent reality: many of the newest cancer therapies are leaving behind a different kind of burden—one that doesn’t always end when treatment does.

For decades, the conversation around cancer recovery has focused heavily on surgery, chemotherapy, and radiation. While these remain major contributors to long-term morbidity, the landscape has changed. Modern oncology now includes immunotherapy, targeted therapies, HER2-directed treatments, stem cell and bone marrow transplants, and other precision-based interventions that can profoundly alter a patient’s physiology. These treatments are saving lives—but they are also creating a growing population of survivors living with chronic and sometimes permanent complications.

This is exactly why rehabilitation in cancer care must evolve.

As Dr. Ben Ho Park points out, “with all these great new therapies come also and unfortunately, new chronic side effects.” That statement captures a major blind spot in survivorship medicine. Too often, the success of treatment is measured only by tumor response or remission status, while the patient’s long-term functional decline, organ injury, or inflammatory burden remains underrecognized.

Immunotherapy is a powerful example. These agents have transformed the outlook for many cancers by enabling the immune system to attack malignant cells more effectively. Yet they can also trigger immune-related adverse effects that persist long after treatment is over. Some patients may experience permanent damage to endocrine organs such as the adrenal glands, thyroid, or pancreas—conditions that can fundamentally alter metabolism, energy regulation, and quality of life. What may begin as a treatment response can ultimately become a lifelong endocrine disorder requiring ongoing management and monitoring.

Similarly, bone marrow and stem cell transplant survivors often face one of the most difficult chronic complications in oncology: graft-versus-host disease (GVHD). In its chronic form, GVHD can behave like a systemic autoimmune illness, affecting the skin, lungs, joints, gastrointestinal tract, eyes, and connective tissues. In some patients, it can resemble diseases such as scleroderma in both symptoms and severity. These are not minor residual effects. They can impair mobility, breathing, digestion, resilience, and the basic ability to function comfortably in everyday life.

Other newer therapies bring their own risks. HER2-directed therapies, while highly effective in breast and other HER2-positive cancers, can in some cases contribute to cardiac dysfunction or heart failure. Additional targeted therapies may affect vascular health, nerve function, inflammatory pathways, or organ performance in ways that are not always immediately visible—but are deeply felt by patients over time.

This is where RehabScan enters the conversation with urgency and relevance.

If cancer treatment is becoming more biologically sophisticated, then rehabilitation must become more diagnostically sophisticated as well. Recovery should no longer be defined only by symptom complaints or generalized supportive care. It should include a structured, measurable effort to identify what systems have been altered, what damage may be lingering beneath the surface, and what interventions can help restore function before decline becomes permanent.

Cancer survivorship is no longer just about being alive after treatment. It is about how well a person is able to live, function, think, move, recover, and reclaim quality of life after the therapies that saved them. The next frontier in oncology is not just better treatment—it is better restoration.

And for many survivors, that may be the care that matters most.

 

PART 2

Redefining Cancer Recovery through Diagnostic Intelligence

By: Dr. Robert L. Bard, Barddiagnostics, NYC

Cancer treatment saves lives—but survival is only the beginning. For millions of patients worldwide, the journey after chemotherapy, radiation, surgery, or immunotherapy is marked not by recovery, but by a new and often overwhelming set of chronic conditions. These are not incidental side effects. They are measurable, evolving physiological disruptions that affect nearly every system of the body. RehabScan™ is designed to meet this moment. It is a next-generation, imaging-supported rehabilitation ecosystem that introduces objective diagnostics into the recovery phase of cancer care, transforming rehabilitation from generalized protocols into precision-guided restoration.

REBUILDING LIFE AFTER CANCER: The Transformative Work of Oncology Rehabilitation

In the evolving landscape of cancer care, survival is no longer the sole benchmark of success. Increasingly, the conversation has shifted toward how patients live after treatment—how they speak, move, eat, think, and reclaim independence. At the forefront of this critical shift is Kaitlin Pennington, an Oncology Rehabilitation Specialist and Founder & CEO of Cancer Rehab Group and Restorative Health & Wellness, whose work is redefining what recovery truly means.

For Pennington, cancer rehabilitation is not an optional service—it is an essential extension of treatment. As she explains through her clinical philosophy, rehabilitation must begin at the moment of diagnosis, not after treatment ends. Baseline function, risk assessment, and proactive intervention are key to preserving quality of life. “It’s critical that it starts at the time of diagnosis,” she emphasizes, noting that early intervention can significantly reduce long-term functional decline .

Rehabilitation as a Missing Link in Cancer Care

Modern cancer treatments, while life-saving, can be profoundly taxing on the body. Radiation fibrosis, surgical trauma, neurological changes, and systemic side effects often leave patients struggling with basic functions long after treatment ends. Pennington’s work addresses this overlooked phase—the “aftermath” of cancer therapy. Her approach integrates:

· Speech and swallowing rehabilitation

· Physical and occupational therapy

· Nutritional guidance

· Mental health support

· Exercise oncology

Together, these disciplines form a comprehensive system designed not only to restore function but to prevent deterioration. The need is urgent. Many patients, particularly those treated years ago, were never offered rehabilitation. They adapt to dysfunction, believing it is irreversible. Pennington challenges this assumption daily.

PART 3

REHAB FOR POSTOP PATIENTS

By Cheri Ambrose (Op-Ed) - Male Breast Cancer Global Alliance

There are more cancer survivors today than ever before—and that should be a victory worth celebrating. But what we don’t talk about enough is the condition of those survivors after treatment ends. Too many are left navigating a quiet aftermath: a body that doesn’t function the way it used to, a mind that feels unfamiliar, and a life that has been altered in ways no one fully prepared them for.

We have spent decades focused on detection and treatment. We’ve made extraordinary strides in saving lives. But survival is not the finish line—it is the beginning of a new phase that demands just as much attention. And right now, that phase is underserved, underfunded, and misunderstood.

 I’ve spoken to countless patients—men and women—who are told, “This is just what happens after chemo.” They are expected to accept neuropathy, chronic fatigue, cognitive impairment, emotional distress, and hormonal disruption as the cost of survival. But I reject that. We should all reject that. Because survival without quality of life is not enough. We need to redefine what rehabilitation truly means in cancer care.

Traditionally, rehab has been reduced to physical therapy—range of motion, strength building, and basic function. But what I see every day tells a very different story. Post-treatment patients are dealing with multi-system damage. They are struggling with what we call “chemo brain,” where memory, focus, and clarity are compromised. They are experiencing neuropathy that affects their ability to walk, drive, or even hold a pen. They are facing lymphedema that alters their physical comfort and confidence. And many are quietly battling depression, anxiety, and loss of identity.